

Supplementary Table 1. Risk factor analysis for recurrence within 5 years using BCLC staging system (overall patients, n=1,451)

Variable	Unadjusted		Multivariable	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age ≥60 vs. <60 (years)	1.18 (1.02–1.35)	0.025	1.11 (0.95–1.30)	0.199
Male vs. female	1.21 (1.02–1.44)	0.032	1.40 (1.17–1.67)	<0.001
Diabetes	1.01 (0.85–1.20)	0.893		
HBV vs. others	0.87 (0.74–1.02)	0.089	1.02 (0.85–1.22)	0.844
ALBI grade 2 vs. 1	1.32 (1.16–1.52)	<0.001	1.21 (1.04–1.40)	0.013
FIB-4 ≥3.25 vs. <3.25	1.46 (1.28–1.68)	<0.001	1.17 (0.99–1.37)	0.056
AFP ≥10 vs. <10 (ng/mL)	1.39 (1.21–1.60)	<0.001	1.49 (1.29–1.72)	<0.001
BCLC A vs. 0	1.16 (1.00–1.34)	0.054	1.44 (1.24–1.69)	<0.001
Initial treatment modality				
Resection	Reference		Reference	
RFA*	1.78 (1.55–2.04)	<0.001	1.90 (1.64–2.21)	<0.001

BCLC, Barcelona Clinic Liver Cancer; HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; ALBI, albumin-bilirubin; FIB-4 score, fibrosis-4 score; AFP, alpha-fetoprotein; RFA, radiofrequency ablation.

*Thirteen patients who received resection and radiofrequency ablation simultaneously were included in this category.